Podcasts

E-Books

Videos

Articles

Clinical

Tony Hagen is senior managing editor for The Center for Biosimilars

Three-fourths of patients who reverse-switched to originator infliximab from CT-P13 benefited, although it wasn't clear why the biosimilar treatment "failed." 

Study: Nocebo Is Likely Cause for Reverse Switching in IBD

Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.

Study: Biosimilar Use Varies by Type of Institution and Physician Characteristics

In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.

Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive

The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.

Nurses Can Counter Nocebo Effect in Biosimilar Switching

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Economists Probe Cost-Effectiveness of Biosimilars

A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar. 

Romiplostim Biosimilar Study Demonstrates Safety, Efficacy in Real-World India Population

The merger of Pfizer's Upjohn division and Mylan has created a biosimilars powerhouse with global reach. 

Newly Created Viatris Joins the Biosimilars Forum

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them. 

Opinion: Embrace the Era of Next-Generation Biologics

Investigators said their study is valuable because biosimilar switching is likely to increase for economic reasons. 

Dermatology